Article

FDA approves combination suspension for glaucoma

The FDA has approved Simbrinza suspension (Alcon) for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

 

Basel, Switzerland-The FDA has approved Simbrinza suspension (Alcon) for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

The medication is a fixed-dose combination that offers a wide range of treatment possibilities due to its strong efficacy and ability to decrease elevated IOP by 21% to 35%. In addition, it is the only available, fixed-dose combination therapy for glaucoma in the United States that does not contain a beta blocker.

“Given its excellent efficacy, established safety profile, and the fact that it is the only available fixed-dose combination without a beta blocker approved in the United States, Simbrinza has the potential to re-shape the treatment paradigm for glaucoma,” said Robert Warner, area president, United States and Canada for Alcon.

The new ophthalmic suspension is a fixed-dose combination of a carbonic anhydrase inhibitor (brinzolamide 1.0%) and an alpha-2 adrenergic receptor agonist (brimonidine tartrate 0.2%) combined into one multi-dose bottle.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.